Abstract
Introduction: Intravaginal delivery is currently considered to be an important alternative route for poorly-absorbed, rapidly metabolised oral drugs.
Objectives: The objective of this study was to evaluate (i) the preliminary feasibility of using the readyto- use vehicle Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and (ii) the vaginal administration of theses formulations to patients with pelvic pain associated with endometriosis (PPRE).
Methods: Intravaginal creams were compounded containing the active pharmaceutical ingredients (APIs) individually and with no addition of permeation enhancers (dienogest 0,2%, gestrinone 0,5%, nimesulide 2,0% and piroxicam 2,0%). For quality control, pH, drug content and particle size were determined. HPLC methods were developed and validated for each formulation. Vaginal permeation profiles were determined using porcine vaginal mucosa on Franz-type diffusion cells and then kinetics parameters were determined.
Results: Quality control of the formulations showed that the products were convenient and easily prepared, with narrow size distribution. Diffusion experiments demonstrated fluxes of 15.98 µg.cm-2.h-1 for dienogest, 3.91 µg.cm-2.h-1 for piroxicam, 3.72 µg.cm-2.h-1 for gestrinone and 2.26 µg.cm-2.h-1 for nimesulide. Dienogest and gestrinone had permeation fluxes and quantities of drug absorbed hypothetically compatible with therapeutic effect in vivo (fluxes to attempt in order to deliver the recommended daily doses to treat PPRE were calculated as 0.87 µg.cm-2.h-1 for dienogest, 0.69 µg.cm-2.h-1 for gestrinone, 70.45 µg.cm-2.h-1 for nimesulide and 9.64 µg.cm-2.h-1 for piroxicam), whereas nimesulide and piroxicam studies showed a great amount of these drugs retained in the vaginal mucosa. This could account for a local effect for these two substances.
Conclusion: Pentravan®, which already has an established role for transdermal delivery of drugs, seems to be a feasible intravaginal vehicle. Particularly in this study, we highlight its use for vaginal delivery of dienogest and gestrinone for the treatment of PPRE. In vivo studies must now be conducted to confirm these data.
Keywords: Vaginal delivery, permeation kinetics, pentravan, franz-type diffusion cell, dienogest, gestrinone, nimesulide, piroxicam.
Graphical Abstract
Drug Delivery Letters
Title:Feasibility Study Evaluating Pentravan® for the Intravaginal Administration of Active Pharmaceutical Ingredients to Reduce Pelvic Pain Related to Endometriosis
Volume: 8 Issue: 3
Author(s): Hudson Polonini*, Sharlene Loures, Michele C. Alves, Anderson O. Ferreira, Marcos Antônio F. Brandão and Nádia R. B. Raposo
Affiliation:
- Ortofarma – Quality Control Laboratory, Matias Barbosa – MG,Brazil
Keywords: Vaginal delivery, permeation kinetics, pentravan, franz-type diffusion cell, dienogest, gestrinone, nimesulide, piroxicam.
Abstract: Introduction: Intravaginal delivery is currently considered to be an important alternative route for poorly-absorbed, rapidly metabolised oral drugs.
Objectives: The objective of this study was to evaluate (i) the preliminary feasibility of using the readyto- use vehicle Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and (ii) the vaginal administration of theses formulations to patients with pelvic pain associated with endometriosis (PPRE).
Methods: Intravaginal creams were compounded containing the active pharmaceutical ingredients (APIs) individually and with no addition of permeation enhancers (dienogest 0,2%, gestrinone 0,5%, nimesulide 2,0% and piroxicam 2,0%). For quality control, pH, drug content and particle size were determined. HPLC methods were developed and validated for each formulation. Vaginal permeation profiles were determined using porcine vaginal mucosa on Franz-type diffusion cells and then kinetics parameters were determined.
Results: Quality control of the formulations showed that the products were convenient and easily prepared, with narrow size distribution. Diffusion experiments demonstrated fluxes of 15.98 µg.cm-2.h-1 for dienogest, 3.91 µg.cm-2.h-1 for piroxicam, 3.72 µg.cm-2.h-1 for gestrinone and 2.26 µg.cm-2.h-1 for nimesulide. Dienogest and gestrinone had permeation fluxes and quantities of drug absorbed hypothetically compatible with therapeutic effect in vivo (fluxes to attempt in order to deliver the recommended daily doses to treat PPRE were calculated as 0.87 µg.cm-2.h-1 for dienogest, 0.69 µg.cm-2.h-1 for gestrinone, 70.45 µg.cm-2.h-1 for nimesulide and 9.64 µg.cm-2.h-1 for piroxicam), whereas nimesulide and piroxicam studies showed a great amount of these drugs retained in the vaginal mucosa. This could account for a local effect for these two substances.
Conclusion: Pentravan®, which already has an established role for transdermal delivery of drugs, seems to be a feasible intravaginal vehicle. Particularly in this study, we highlight its use for vaginal delivery of dienogest and gestrinone for the treatment of PPRE. In vivo studies must now be conducted to confirm these data.
Export Options
About this article
Cite this article as:
Polonini Hudson*, Loures Sharlene, Alves C. Michele, Ferreira O. Anderson, Brandão Antônio F. Marcos and Raposo R. B. Nádia, Feasibility Study Evaluating Pentravan® for the Intravaginal Administration of Active Pharmaceutical Ingredients to Reduce Pelvic Pain Related to Endometriosis, Drug Delivery Letters 2018; 8 (3) . https://dx.doi.org/10.2174/2210303108666180319164824
DOI https://dx.doi.org/10.2174/2210303108666180319164824 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease
Current Alzheimer Research Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology Prospects for Gene Therapy of Osteopetrosis
Current Gene Therapy Therapeutic Genes for Anti-HIV/AIDS Gene Therapy
Current Pharmaceutical Biotechnology Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients
Recent Patents on Anti-Cancer Drug Discovery Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design The Role of PrP in Health and Disease
Current Molecular Medicine The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design